Supplementary Material for: Adalimumab and Tofacitinib Combination Therapy for Pyoderma Gangrenosum: A case report

Introduction: Pyoderma gangrenosum (PG) is a rare inflammatory skin disease causing progressive necrotizing ulcers with limited treatment options due to adverse effects and high recurrence rates. Case Presentation: We present a case of a 70-year-old elderly patient diagnosed as PG, which was unresponsive to initial prednisolone treatment. After approximately three weeks of an individualized treatment regimen of adalimumab combined with tofacitinib, disease progression was halted, accompanied by a significant reduction in ulcer size, reduced exudation, and substantial pain relief. Subsequent tapering and discontinuation of prednisolone, followed by six weeks of combined adalimumab and tofacitinib and eight weeks of tofacitinib monotherapy, resulted in complete ulcer healing by week 17. No recurrence of inflammatory activity was observed during the follow-up period of over 7 months.